Bryan H. Louie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bryan H. Louie has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Hyo Jeong Lim
Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea
3 shared publicationsKi Hwan Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea
3 shared publicationsRazelle Kurzrock
WIN Consortium for Precision Medicine, Paris, France
3 shared publications- Howard Y. Chang
Departments of Dermatology, Genetics, and Pathology, Stanford University School of Medicine, Stanford, USA
2 shared publications Jeffrey M. Granja
Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA
2 shared publicationsMaxwell R. Mumbach
Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA
2 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (6) , 108681
Initial Experience with Robotic-Assisted CT-Guided Ablation: Analysis from a Single Center’s Learning Curve in the First 54 Patients
- 27 February 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (6) , 108681
Open AccessInitial Experience with Robotic-Assisted CT-Guided Ablation: Analysis from a Single Center’s Learning Curve in the First 54 Patients
- Open Access
- 22 September 2022
- Published by Springer Nature in npj Precision Oncology
- Vol. 6 (1) , 1-8
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics to develop N-of-One therapies for patients in the pan-cancer, advanced, refractory setting. This study evaluates the experience of 80 patients who were presented to the MTB and received a treatment regimen that included ICB. Overall, 60/80 patients (75%) who received ICB following MTB discussion had a high degree of matching between tumor molecular characteristics, including ICB biomarkers (reflected by a high Matching Score (≥50%)) and therapy administered. Patients with high versus low Matching Score experienced significantly longer median progression-free survival (6.4 vs. 3.0 months; p = 0.011) and median overall survival (15.3 vs. 4.7 months; p = 0.014) and higher clinical benefit rates (stable disease ≥6 months/partial response/complete response) (53% vs. 21%, p = 0.019). Although most patients (52/80 (65%)) received a personalized combination therapy (e.g., targeted, hormonal, chemotherapy, or a second immunotherapy agent), administering >1 drug was not associated with outcome. Only degree of matching and age, but no other variables, including individual biomarkers (e.g., microsatellite status, tumor mutational burden, or PD-L1 status), were independently correlated with outcome. In the pan-cancer setting, the MTB facilitated a precision medicine strategy to match therapeutic regimens that included ICB alone or combined with matched targeted drugs to patients with advanced malignancy, which was associated with improved clinical outcomes.
- 22 September 2022
- Published by Springer Nature in npj Precision Oncology
- Vol. 6 (1) , 1-8
Open AccessPan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics to develop N-of-One therapies for patients in the pan-cancer, advanced, refractory setting. This study evaluates the experience of 80 patients who were presented to the MTB and received a treatment regimen that included ICB. Overall, 60/80 patients (75%) who received ICB following MTB discussion had a high degree of matching between tumor molecular characteristics, including ICB biomarkers (reflected by a high Matching Score (≥50%)) and therapy administered. Patients with high versus low Matching Score experienced significantly longer median progression-free survival (6.4 vs. 3.0 months; p = 0.011) and median overall survival (15.3 vs. 4.7 months; p = 0.014) and higher clinical benefit rates (stable disease ≥6 months/partial response/complete response) (53% vs. 21%, p = 0.019). Although most patients (52/80 (65%)) received a personalized combination therapy (e.g., targeted, hormonal, chemotherapy, or a second immunotherapy agent), administering >1 drug was not associated with outcome. Only degree of matching and age, but no other variables, including individual biomarkers (e.g., microsatellite status, tumor mutational burden, or PD-L1 status), were independently correlated with outcome. In the pan-cancer setting, the MTB facilitated a precision medicine strategy to match therapeutic regimens that included ICB alone or combined with matched targeted drugs to patients with advanced malignancy, which was associated with improved clinical outcomes.
- Open Access
- 8 April 2022
- Published by Wiley in Molecular Oncology
- Vol. 16 (13) , 2575-2584
Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
Treatment for advanced colorectal cancer is often limited by complex molecular profiles, which promote resistance to systemic agents and targeted monotherapies. Recent studies suggest that a personalized, combinatorial approach of matching drugs to tumor alterations may be more effective. We implemented a precision medicine strategy by forming a Molecular Tumor Board (MTB), a multidisciplinary team of clinicians, scientists, bioinformaticians and geneticists. The MTB integrated molecular profiling information and patient characteristics to develop N‐of‐One treatments for 51 patients with advanced colorectal cancer. All patients had metastatic disease and 63% had received ≥ 3 prior therapy lines. Overall, 34/51 patients (67%) were matched to ≥ 1 drug recommended by the MTB based on individual tumor characteristics, whereas 17/51 (33%) patients received unmatched therapies. Patients who received matched therapy demonstrated significantly longer progression‐free survival (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.21–0.81;P = 0.01) and a trend towards higher clinical benefit rates (41% vs. 18%,P = 0.058) (all multivariate) compared to patients receiving unmatched therapy. The MTB facilitated personalized matching of drugs to tumor characteristics, which was associated with improved progression‐free survival in patients with advanced colorectal cancer.
- 8 April 2022
- Published by Wiley in Molecular Oncology
- Vol. 16 (13) , 2575-2584
Open AccessPrecision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
Treatment for advanced colorectal cancer is often limited by complex molecular profiles, which promote resistance to systemic agents and targeted monotherapies. Recent studies suggest that a personalized, combinatorial approach of matching drugs to tumor alterations may be more effective. We implemented a precision medicine strategy by forming a Molecular Tumor Board (MTB), a multidisciplinary team of clinicians, scientists, bioinformaticians and geneticists. The MTB integrated molecular profiling information and patient characteristics to develop N‐of‐One treatments for 51 patients with advanced colorectal cancer. All patients had metastatic disease and 63% had received ≥ 3 prior therapy lines. Overall, 34/51 patients (67%) were matched to ≥ 1 drug recommended by the MTB based on individual tumor characteristics, whereas 17/51 (33%) patients received unmatched therapies. Patients who received matched therapy demonstrated significantly longer progression‐free survival (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.21–0.81;P = 0.01) and a trend towards higher clinical benefit rates (41% vs. 18%,P = 0.058) (all multivariate) compared to patients receiving unmatched therapy. The MTB facilitated personalized matching of drugs to tumor characteristics, which was associated with improved progression‐free survival in patients with advanced colorectal cancer.
- Top Cited PapersOpen Access
- 20 August 2020
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 90, 102091
BAP1: Not just a BRCA1-associated protein
- 20 August 2020
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 90, 102091
Top Cited PapersOpen AccessBAP1: Not just a BRCA1-associated protein
- 27 May 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (6) , 489-492
HiChIRP reveals RNA-associated chromosome conformation
Modular domains of long non-coding RNAs can serve as scaffolds to bring distant regions of the linear genome into spatial proximity. Here, we present HiChIRP, a method leveraging bio-orthogonal chemistry and optimized chromosome conformation capture conditions, which enables interrogation of chromatin architecture focused around a specific RNA of interest down to approximately ten copies per cell. HiChIRP of three nuclear RNAs reveals insights into promoter interactions (7SK), telomere biology (telomerase RNA component) and inflammatory gene regulation (lincRNA-EPS).
- 27 May 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (6) , 489-492
HiChIRP reveals RNA-associated chromosome conformation
Modular domains of long non-coding RNAs can serve as scaffolds to bring distant regions of the linear genome into spatial proximity. Here, we present HiChIRP, a method leveraging bio-orthogonal chemistry and optimized chromosome conformation capture conditions, which enables interrogation of chromatin architecture focused around a specific RNA of interest down to approximately ten copies per cell. HiChIRP of three nuclear RNAs reveals insights into promoter interactions (7SK), telomere biology (telomerase RNA component) and inflammatory gene regulation (lincRNA-EPS).
- Top Cited Papers
- 26 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 362 (6413) , 420-+
The chromatin accessibility landscape of primary human cancers
Cancer chromatin accessibility landscape: The Cancer Genome Atlas (TCGA) provides a high-quality resource of molecular data on a large variety of human cancers. Corces et al. used a recently modified assay to profile chromatin accessibility to determine the accessible chromatin landscape in 410 TCGA samples from 23 cancer types (see the Perspective by Taipale). When the data were integrated with other omics data available for the same tumor samples, inherited risk loci for cancer predisposition were revealed, transcription factors and enhancers driving molecular subtypes of cancer with patient survival differences were identified, and noncoding mutations associated with clinical prognosis were discovered. Science , this issue p. eaav1898 ; see also p. 401
- 26 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 362 (6413) , 420-+
Top Cited PapersThe chromatin accessibility landscape of primary human cancers
Cancer chromatin accessibility landscape: The Cancer Genome Atlas (TCGA) provides a high-quality resource of molecular data on a large variety of human cancers. Corces et al. used a recently modified assay to profile chromatin accessibility to determine the accessible chromatin landscape in 410 TCGA samples from 23 cancer types (see the Perspective by Taipale). When the data were integrated with other omics data available for the same tumor samples, inherited risk loci for cancer predisposition were revealed, transcription factors and enhancers driving molecular subtypes of cancer with patient survival differences were identified, and noncoding mutations associated with clinical prognosis were discovered. Science , this issue p. eaav1898 ; see also p. 401